Frost et al. showed that patients with the KRAS mutation G12C, high PD-L1 expression on tumor cells, and functional TP53 mutations are long-term responders to first-line palliative treatment with pembrolizumab monotherapy in advanced tumor stages [54]. This evidence concerns the gene KRAS and neoplasm.